GI 4000

Drug Profile

GI 4000

Alternative Names: GI-4000

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator GlobeImmune
  • Class Cancer vaccines
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 19 Apr 2017 NantCell plans the phase Ib/II QUILT-3.039 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) (NCT03136406)
  • 16 Mar 2016 Phase II development of GI 4000 is contingent on identifying additional sources of financing (GlobeImmune, Form 10-K, March 2016).
  • 16 Mar 2016 Efficacy data from a phase IIa trial in Non-small cell lung cancer released by GlobeImmune (GlobeImmune, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top